Drug Profile
Vornorexant - Taisho Pharmaceutical
Alternative Names: ORN-0829; TS-142Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Class Fluorinated hydrocarbons; Oxazines; Pyrazoles; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Insomnia
- No development reported Sleep apnoea syndrome
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Sleep-apnoea-syndrome(In the elderly, In adults) in Japan (PO, Tablet)
- 07 Mar 2024 Taisho Pharmaceutical completes a phase III trial for Insomnia in Japan (PO, Tablets) (NCT05461352)
- 08 Dec 2023 Taisho Pharmaceutical completes a phase I pharmacokinetic trial (In volunteers) in Japan (PO) (NCT05624944)